Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 3 Interventional

A Study to Investigate Efficacy and Safety of Pegtibatinase Compared With Placebo in Participants ≥12 to ≤65 Years of Age With Classical Homocystinuria (HCU) Due to Cystathionine Beta Synthase Deficiency Receiving Standard of Care Treatment

ClinicalTrials.gov ID: NCT06247085

Public ClinicalTrials.gov record NCT06247085. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 6, 2026, 12:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Parallel-Group Treatment, Blinded, Randomized, Placebo-Controlled Study To Assess The Efficacy And Safety Of Pegtibatinase Administered Subcutaneously In Addition To Standard Of Care In Participants With Classical Homocystinuria Due To Cystathionine Beta Synthase Deficiency (HARMONY)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to measure efficacy and safety of pegtibatinase treatment compared with placebo in participants with classical HCU receiving standard of care. Study details include: * Total Study duration: up to 38 weeks * Screening: * Initial Screening duration: up to 4 weeks * Pre-treatment Diet Standardization Period duration: up to 6 weeks * Blinded Treatment Duration: 24 weeks * 2-week blinded dose titration period * 22-week blinded assessment period * Safety Follow-Up: 4 weeks after last dose (as applicable for those not enrolling in the long term extension study, ENSEMBLE)

Study identification

NCT ID
NCT06247085
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Travere Therapeutics, Inc.
Industry
Enrollment
70 participants

Conditions and interventions

Conditions

Interventions

Drug · Other

Eligibility (public fields only)

Age range
12 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 27, 2023
Primary completion
Jul 31, 2027
Completion
Aug 31, 2027
Last update posted
Aug 6, 2026

2023 – 2027

United States locations

U.S. sites
13
U.S. states
12
U.S. cities
13
Facility City State ZIP Site status
Phoenix Children's Hospital Phoenix Arizona 85006 Recruiting
Yale University School of Medicine New Haven Connecticut 06519 Recruiting
Emory University Atlanta Georgia 30322 Recruiting
Ann & Robert H. Lurie Children's Hospital of Chicago Chicago Illinois 60611 Not yet recruiting
Maine Health - Maine Medical Center Portland Maine 04102 Recruiting
Uncommon Cures Chevy Chase Maryland 20815 Recruiting
The Mount Sinai Hospital New York New York 10029 Recruiting
Science 37 - Virtual Site Morrisville North Carolina 27560 Recruiting
Oregon Health and Science University Portland Oregon 97239 Not yet recruiting
Children's Hospital of Philadelphia Philadelphia Pennsylvania 19104 Recruiting
University of Pittsburgh Medical Center - Children's Hospital of Pittsburgh Pittsburgh Pennsylvania 15224 Recruiting
University of Texas Southwestern Medical Center Dallas Texas 75390 Recruiting
Utah Health - The University of Utah Primary Children's Hospital Salt Lake City Utah 84113 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 39 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06247085, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 6, 2026 · Synced Sep 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06247085 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →